| Schedule of segment reporting information |
| Schedule of segment reporting information |
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Total revenues |
|
|
|
|
|
|
|
|
| US |
|
$ |
12,161 |
|
|
$ |
11,112 |
|
| International |
|
|
- |
|
|
|
59,476 |
|
| Total revenues |
|
|
12,161 |
|
|
|
70,588 |
|
| Less: |
|
|
|
|
|
|
|
|
| Cost of revenues (excluding amortization and depreciation) |
|
|
3,264 |
|
|
|
22,838 |
|
| Research and development expense
(excluding stock based compensation expense): |
|
|
|
|
|
|
|
|
| Clinical trials |
|
|
457,975 |
|
|
|
60,226 |
|
| EDC Build |
|
|
53,795 |
|
|
|
61,950 |
|
| Halo project |
|
|
20,780 |
|
|
|
90,534 |
|
| SYNC project |
|
|
16,451 |
|
|
|
11,700 |
|
| Other research and development |
|
|
15,479 |
|
|
|
1,364 |
|
| Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense) |
|
|
852,838 |
|
|
|
687,011 |
|
| Depreciation |
|
|
2,738 |
|
|
|
- |
|
| Amortization |
|
|
20,325 |
|
|
|
5,126 |
|
| Stock based compensation |
|
|
408,387 |
|
|
|
572,100 |
|
| Professional fees |
|
|
407,444 |
|
|
|
178,597 |
|
| Interest income, net |
|
|
(129 |
) |
|
|
(4,690 |
) |
| Other income |
|
|
(8,016 |
) |
|
|
(35,181 |
) |
| Segment net loss |
|
|
(2,239,170 |
) |
|
|
(1,580,987 |
) |
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Adjustments and reconciling items |
|
|
- |
|
|
|
- |
|
| Consolidated net loss |
|
$ |
(2,239,170 |
) |
|
$ |
(1,580,987 |
) |
| |
|
|
|
|
|
|
|
|
| |
|
Six Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Total revenues |
|
|
|
|
|
|
|
|
| US |
|
$ |
27,111 |
|
|
$ |
31,555 |
|
| International |
|
|
- |
|
|
|
80,048 |
|
| Total revenues |
|
|
27,111 |
|
|
|
111,603 |
|
| Less: |
|
|
|
|
|
|
|
|
| Cost of revenues (excluding amortization and depreciation) |
|
|
5,081 |
|
|
|
36,396 |
|
| Research and development expense
(excluding stock based compensation expense): |
|
|
|
|
|
|
|
|
| Clinical trials |
|
|
656,421 |
|
|
|
121,578 |
|
| EDC Build |
|
|
109,595 |
|
|
|
80,000 |
|
| Halo project |
|
|
109,547 |
|
|
|
388,571 |
|
| SYNC project |
|
|
16,451 |
|
|
|
35,413 |
|
| Other research and development |
|
|
18,848 |
|
|
|
6,500 |
|
| Selling, general and administrative and Salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense) |
|
|
1,654,742 |
|
|
|
1,309,959 |
|
| Depreciation |
|
|
6,844 |
|
|
|
- |
|
| Amortization |
|
|
27,061 |
|
|
|
9,912 |
|
| Stock based compensation |
|
|
886,998 |
|
|
|
1,208,944 |
|
| Professional fees |
|
|
902,740 |
|
|
|
546,413 |
|
| Interest income, net |
|
|
(163 |
) |
|
|
(5,793 |
) |
| Equity in net income from equity method investees |
|
|
- |
|
|
|
1,048 |
|
| Other income |
|
|
(31,047 |
) |
|
|
(58,014 |
) |
| Segment net loss |
|
|
(4,336,007 |
) |
|
|
(3,569,324 |
) |
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Adjustments and reconciling items |
|
|
- |
|
|
|
- |
|
| Consolidated net loss |
|
$ |
(4,336,007 |
) |
|
$ |
(3,569,324 |
) |
|